Key result
Patient-managed thumb ECG was feasible for detecting atrial fibrillation recurrence after cardioversion, with 75.0% of patients fully adherent and 50.3% detecting recurrence within 4 weeks.
Why the study?
Recurrence rates after electrical cardioversion for persistent AF are high, and patients often fail to recognize AF recurrence.
Is patient-managed thumb ECG feasible for detecting atrial fibrillation recurrence after electrical cardioversion?
Observational (n=200)
No
Is patient-managed thumb ECG feasible for detecting atrial fibrillation recurrence after electrical cardioversion?
Patient-managed thumb ECG is a highly feasible method for monitoring atrial fibrillation recurrence after electrical cardioversion, detecting a high rate of asymptomatic recurrences.
Supports patient-managed thumb ECG for post-cardioversion AF monitoring; hypothesis-generating for clinical impact pending RCTs.
BACKGROUND: Electrical cardioversion (ECV) is a common procedure to terminate persistent atrial fibrillation (AF). The recurrence rate is high, and the patients often fail to recognize AF recurrence. OBJECTIVES: The aim of the study was to evaluate the feasibility of patient-managed electrocardiography (ECG) to detect the time to AF recurrence after ECV. METHODS: PRE-ELECTRIC (predictors for recurrence of atrial fibrillation after electrical cardioversion) is a prospective, observational study. Patients ≥18 years of age scheduled for ECV of persistent AF at Bærum Hospital were eligible for inclusion in the study. Time to recurrence of AF was detected by thumb ECG, recorded twice daily and whenever experiencing symptoms. The observation period was 28 days. We defined adherence as the observed number of days with ECG recordings divided by the expected number of days with ECG recordings. Study personnel contacted the participants by phone to assess their awareness of AF recurrence after a recurrence was detected in the thumb ECG. RESULTS: The study enrolled 200 patients scheduled for ECV of persistent AF at Bærum Hospital between 2018 and 2022. The mean age was 66.2 ± 9.3 years, and 21.0% (42/200) were women. The most frequent comorbidities were hypertension (n = 94, 47.0%) and heart failure (n = 51, 25.5%). A total of 164 participants underwent ECV of AF. The procedure was initially successful in 90.9%, of which 50.3% had a recurrence of AF within 4 weeks. The median time to recurrence was 5 days. Among the cardioverted participants, 123 (75.0%) had no missing days of thumb ECG recording during the observation period, and 97.0% had ≤3 missing days. More than a third (37.3%) of the participants with AF recurrence were unaware of the recurrence at the time of contact. Women were older and more symptomatic than men but had similar outcomes after ECV. CONCLUSIONS: Recurrence of AF after ECV was common. Using patient-managed thumb ECG was a feasible method to detect AF recurrence following ECV. Further studies are needed to investigate whether patient-managed ECG after ECV can optimize AF treatment.
No takes yet. Share an insight, caveat, or question.
Andersen et al. (2023) conducted an observational in Persistent atrial fibrillation (n=200). Patient-managed thumb ECG was evaluated on Feasibility of patient-managed ECG to detect time to AF recurrence. Patient-managed thumb ECG was feasible for detecting atrial fibrillation recurrence after cardioversion, with 75.0% of patients fully adherent and 50.3% detecting recurrence within 4 weeks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: